Lasa Supergenerics

Lasa Supergenerics EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Lasa Supergenerics (LASA.NS) as of Nov 3, 2026 is -342.22 M INR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 62.66 M INR — a change of -646.15% (lower).

EBITDA

-342.22 MINR

YoY

-646.15%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Lasa Supergenerics is 2026 -342.22 M INR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Lasa Supergenerics was 2025 62.66 M INR. It decreases by -646.15% lower compared to the previous year.

The Lasa Supergenerics EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
114.70 M INR
Jan 1, 2020
299.69 M INR
Jan 1, 2021
472.65 M INR
Jan 1, 2022
168.36 M INR
Jan 1, 2023
-246.86 M INR
Jan 1, 2024
22.41 M INR
Jan 1, 2025
62.66 M INR
Jan 1, 2026
-342.22 M INR
The Lasa Supergenerics EBITDA history
YEAREBITDAYoY
-342.22 MINR-646.15%
62.66 MINR+179.58%
22.41 MINR-109.08%
-246.86 MINR-246.62%
168.36 MINR-64.38%
472.65 MINR+57.72%
299.69 MINR+161.28%
114.70 MINR-72.22%
412.94 MINR-9.82%
457.91 MINR—
0.00INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Lasa Supergenerics Stock analysis

What does Lasa Supergenerics do? Lasa Supergenerics Ltd manufactures veterinary preparations including API products such as Albendazole, Fenbendazole, Oxfendazole, Providone Iodine, Nitroxylene, Ricobendazole, Halquinol, and others. The company also produces animal feed ingredients like potassium iodide, cobalt sulfate, sodium selenate, ethylediamine dihydroiodide, and vanadyl sulfate, as well as reagents for therapeutic use including cetylpyridinium chloride, bismuth subsalicylate, and sodium selenite. Its manufacturing facility in Mahad and Chiplun, Maharashtra, supports the production of these specialized veterinary and pharmaceutical products. The company's primary customers are likely veterinary pharmaceutical manufacturers and animal health suppliers who require API products, feed additives, and therapeutic reagents. These segments include the veterinary pharmaceutical industry and animal feed production sectors, which rely on Lasa Supergenerics' specialized chemical formulations for their own product lines. The firm's focus on catalyst chemistry and anthelmintic/veterinary API products positions it within the niche market of veterinary pharmaceutical manufacturing. Lasa Supergenerics generates revenue through the sale of its API products, animal feed ingredients, and therapeutic reagents to veterinary and pharmaceutical companies. The company's product portfolio targets the veterinary pharmaceutical sector, where demand for anthelmintic and other API-based solutions is significant. By specializing in catalyst chemistry and producing high-demand veterinary API products, the company serves a specific market segment with tailored chemical solutions. Lasa Supergenerics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lasa Supergenerics stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Lasa Supergenerics is -342.22 M INR in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Lasa Supergenerics changed from 62.66 M INR to -342.22 M INR, representing a -646.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Lasa Supergenerics since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Lasa Supergenerics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Lasa Supergenerics

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Lasa Supergenerics